M. Dolores Delgado

List of Publications by Year
in descending order

47 papers	2,579 citations	186265 28 h-index	223800 46 g-index
50 all docs	50 docs citations	50 times ranked	4875 citing authors

#	Article	IF	Citations
1	Myc and cell cycle control. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 506-516.	1.9	538
2	Myc Roles in Hematopoiesis and Leukemia. Genes and Cancer, 2010, 1, 605-616.	1.9	217
3	MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes, 2019, 10, 244.	2.4	136
4	Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Research, 2007, 35, 7372-7388.	14.5	94
5	Functional Phosphorylation Sites in the C-Terminal Region of the Multivalent Multifunctional Transcriptional Factor CTCF. Molecular and Cellular Biology, 2001, 21, 2221-2234.	2.3	89
6	p21Cip1 and p27Kip1 Induce Distinct Cell Cycle Effects and Differentiation Programs in Myeloid Leukemia Cells. Journal of Biological Chemistry, 2005, 280, 18120-18129.	3.4	81
7	CTCF regulates the local epigenetic state of ribosomal DNA repeats. Epigenetics and Chromatin, 2010, 3, 19.	3.9	80
8	The male germ cell gene regulator CTCFL is functionally different from CTCF and binds CTCF-like consensus sites in a nucleosome composition-dependent manner. Epigenetics and Chromatin, 2012, 5, 8.	3.9	80
9	CTCF Regulates Growth and Erythroid Differentiation of Human Myeloid Leukemia Cells. Journal of Biological Chemistry, 2005, 280, 28152-28161.	3.4	76
10	Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly(ADP-ribosyl)ation-dependent mechanism. Journal of Cell Science, 2006, 119, 1746-1759.	2.0	75
11	Levels of Gli3 repressor correlate withBmp4 expression and apoptosis during limb development. Developmental Dynamics, 2004, 231, 148-160.	1.8	60
12	c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene, 2000, 19, 2194-2204.	5.9	58
13	Identification of a Candidate Tumor-Suppressor Gene Specifically Activated during Ras-Induced Senescence. Experimental Cell Research, 2002, 273, 127-137.	2.6	58
14	Inhibition of cell differentiation: A critical mechanism for MYC-mediated carcinogenesis?. Cell Cycle, 2009, 8, 1148-1157.	2.6	54
15	MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib. Molecular Cancer Research, 2011, 9, 564-576.	3.4	54
16	MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1. Oncogene, 2013, 32, 2239-2246.	5.9	54
17	H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene, 2000, 19, 783-790.	5.9	53
18	Myc Inhibits p27-Induced Erythroid Differentiation of Leukemia Cells by Repressing Erythroid Master Genes without Reversing p27-Mediated Cell Cycle Arrest. Molecular and Cellular Biology, 2008, 28, 7286-7295.	2.3	53

#	Article	IF	Citations
19	Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Oncogene, 1997, 14, 1315-1327.	5.9	51
20	MYC oncogene in myeloid neoplasias. Clinical and Translational Oncology, 2013, 15, 87-94.	2.4	51
21	Effects of the antitumoural dequalinium on NB4 and K562 human leukemia cell lines. Leukemia Research, 2005, 29, 1201-1211.	0.8	50
22	Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production. Leukemia Research, 2007, 31, 969-978.	0.8	50
23	Apoptosis and Mitotic Arrest Are Two Independent Effects of the Protein Phosphatases Inhibitor Okadaic Acid in K562 Leukemia Cells. Biochemical and Biophysical Research Communications, 1999, 260, 256-264.	2.1	42
24	p21 as a Transcriptional Co-Repressor of S-Phase and Mitotic Control Genes. PLoS ONE, 2012, 7, e37759.	2.5	42
25	The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis. Clinical Cancer Research, 2006, 12, 5978-5986.	7.0	41
26	Transcription Factors Sp1 and p73 Control the Expression of the Proapoptotic Protein NOXA in the Response of Testicular Embryonal Carcinoma Cells to Cisplatin. Journal of Biological Chemistry, 2012, 287, 26495-26505.	3.4	41
27	A Cell Cycle Role for the Epigenetic Factor CTCF-L/BORIS. PLoS ONE, 2012, 7, e39371.	2.5	37
28	Differential expression and phosphorylation of CTCF, a c-myctranscriptional regulator, during differentiation of human myeloid cells. FEBS Letters, 1999, 444, 5-10.	2.8	31
29	Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells. Scientific Reports, 2019, 9, 16495.	3.3	27
30	Gene expression regulation and cancer. Clinical and Translational Oncology, 2006, 8, 780-787.	2.4	24
31	p21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells. Cancer Letters, 2010, 292, 133-139.	7.2	20
32	Spi-1/PU.1 Proto-oncogene Induces Opposite Effects on Monocytic and Erythroid Differentiation of K562 Cells. Biochemical and Biophysical Research Communications, 1998, 252, 383-391.	2.1	19
33	Down Regulation of C-MYC and MAX Genes Is Associated to Inhibition of Protein Phosphatase 2A in K562 Human Leukemia Cells. Biochemical and Biophysical Research Communications, 1995, 215, 889-895.	2.1	18
34	PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Letters, 2008, 270, 328-336.	7.2	18
35	HCT116 cells deficient in p21Waf1 are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. DNA Repair, 2009, 8, 390-399.	2.8	17
36	Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Molecular Cancer Therapeutics, 2003, 2, 893-900.	4.1	17

#	Article	IF	Citations
37	C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica, 2004, 89, 241-3.	3.5	15
38	Nuclear Targeting of a Bacterial Integrase That Mediates Site-Specific Recombination between Bacterial and Human Target Sequences. Applied and Environmental Microbiology, 2011, 77, 201-210.	3.1	13
39	Interferon Induces Up-regulation of Spi-1/PU.1 in Human Leukemia K562 Cells. Biochemical and Biophysical Research Communications, 1997, 240, 862-868.	2.1	10
40	c-Myc inhibits CD11a and CD11c leukocyte integrin promoters. European Journal of Immunology, 2000, 30, 2465-2471.	2.9	10
41	The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells. Journal of Biological Chemistry, 2020, 295, 2001-2017.	3.4	10
42	Simultaneous occurrence of follicular lymphoma in two monozygotic twins. British Journal of Haematology, 1999, 107, 461-462.	2.5	4
43	Induction of apolipoprotein E expression during erythroid differentiation of human K562 leukemia cells. Leukemia Research, 1993, 17, 771-776.	0.8	3
44	A novel mutation in ADAMTS13 of a child with Upshaw-Schulman Syndrome. Thrombosis and Haemostasis, 2014, 112, 1065-1068.	3.4	3
45	MYC as therapeutic target in leukemia and lymphoma. Blood and Lymphatic Cancer: Targets and Therapy, 0, , 75.	2.7	2
46	The epigenetic regulator CTCF modulates BCL6 in lymphoma. Oncoscience, 2015, 2, 783-784.	2.2	2
47	A novel role of MNT as a negative regulator of REL and the NF-Î²B pathway. Oncogenesis, 2021, 10, 5.	4.9	1